CSG Secures Major NATO Fuse Orders but Stock Drops 17% in a Week as Trust Deficit Persists

New contracts, strong quarterly earnings, and a backlog approaching €17 billion — yet CSG’s shares have shed nearly 17% in seven trading sessions. The disconnect between operational momentum and market sentiment has rarely been starker.

The latest bout of selling came even as the Czechoslovak Group announced two long-term supply agreements for mechanical and electronic fuses used in large-calibre ammunition. The contracts, signed on 3 June with two European NATO members, carry a combined value in the high tens of millions of euros. Deliveries are scheduled to begin before the end of 2026.

The orders are the first fruits of a joint venture announced in May between CSG and South African defence group Reunert. The pair are setting up Fuchs Electronics Europe in Slovakia, with Reunert holding 51% and CSG 49%. Production will take place at the ZVS holding site in Dubnica nad Váhom. The venture will not only supply CSG but also open its doors to other European munitions makers, positioning CSG as one of the few EU producers of electronic fuses. A binding initial order covers the three-year ramp-up phase, after which Fuchs is expected to become self-sustaining.

The market’s response to the deals was muted at best. On Friday, shares closed at €15.05, down 3.62% on the day alone, extending the weekly rout to 16.68%. The stock now trades 23.44% below its 50-day moving average of €19.66 and more than 58% below the 52-week high of €36.05 hit in late January. The gap to the May low of €13.65 has narrowed to just over 10%.

Should investors sell immediately? Or is it worth buying CSG?

The persistent weakness has its roots in a report published by short-seller Hunterbrook Capital in May. The firm alleged that CSG resells or refurbishes more ammunition than it actually manufactures — a distinction that matters because markets price manufacturers and traders very differently. CSG lost roughly 13% in a single day. The company rejected the allegations, reiterated its capacity targets, and stuck to its plan to boost in-house production by around 20% in 2026, aiming for 1.1 million rounds annually from plants in Slovakia, Greece, Serbia, Spain and India. A second Hunterbrook report focusing on Southeast Asian ties followed, which CSG dismissed as selective interpretation of public data to support a short position.

Operationally, the numbers tell a different story. In its first quarterly results as a listed company, CSG reported revenue up 13.8% to €1.544 billion, with the order book swelling to roughly €17 billion. The stock initially recouped between 11% and 13% — nearly all the short-seller losses — but that recovery has since evaporated. The company reaffirmed its full-year 2026 revenue guidance of €7.4 billion to €7.6 billion and an EBIT margin of 24% to 25%.

Analysts remain broadly bullish despite the price action. Ten rate the shares a buy, none recommend selling. The average price target is €32.05, with the highest forecast at €42. The relative strength index of 31.8 signals oversold conditions, while annualised 30-day volatility of nearly 77% reflects the jittery trading environment. Berenberg, however, has trimmed its estimates after mixed segment results in the first quarter.

CSG at a turning point? This analysis reveals what investors need to know now.

The next inflection point comes on 7 August, when CSG will publish its half-year results. The quiet period begins on 8 July. Until then, the fuze contracts stand as the most tangible evidence the company can offer for its integration strategy — but the market has yet to be convinced.

Ad

CSG Stock: New Analysis - 6 June

Fresh CSG information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated CSG analysis...

en | NL0015073TS8 | CSG | boerse | 69494222 |